What does it really mean for synthetic data to be private? This systematic review digs into 105 studies to map how privacy in SDG is defined, evaluated & applied, spotlighting differential privacy, GANs & healthcare use. 👉Available at: synthema.eu/publications/

#SYNTHEMA is building the foundations for a future where synthetic, privacy-preserving data supports progress in rare diseases. Beyond its two use cases, its flexible design can benefit other rare and underrepresented conditions. More 👉 synthema.eu

In 1 hour, we are starting the final session of the SYNTHEMA and @erneurobloodnet.bsky.social training programme. Today’s session will explore how synthetic data can support research in Sickle Cell Disease and Acute Myeloid Leukaemia. 👉 Register, it’s free: synthema.eu/training/

New publication from the SYNTHEMA project 👇 Researchers developed a two-stage framework to assess privacy risks in Federated Learning and generative AI, showing when client updates remain detectable and can be linked to private data. Access the paper: synthema.eu/publications/

In 1 hour, we are starting the third SYNTHEMA and @erneurobloodnet.bsky.social session. Today’s discussion will focus on interoperability, synthetic data and how health data can be standardised, shared and reused across systems. 👉 Register, it’s free: synthema.eu/training/

Interested in synthetic data and AI-powered breakthroughs in hematology? Visit SYNTHEMA’s publications section to explore the latest advancements by our team in data privacy, federated learning, AI for rare blood diseases, and more. 👉Start reading: synthema.eu/publications #SYNTHEMA #SyntheticData

Starting in 1 hour! Today’s SYNTHEMA and @erneurobloodnet.bsky.social session will focus on the regulatory and ethical context for AI in healthcare, including MDR, the EU AI Act and privacy-preserving federated learning. 👉 Register, it’s free: synthema.eu/training/

The SYNTHEMA M42 meeting in Rome wrapped up after two productive days of collaboration. Partners aligned on the final phase of the project, including the white paper, webinars, and sustainability of results. Thanks to Datawizard for hosting us 🫶 synthema.eu

Saluti da Roma! 🇮🇹 The SYNTHEMA consortium is in Rome this week for the project’s M42 meeting, hosted by Datawizard. Over the next two days, partners will coordinate the final phase of the project as SYNTHEMA enters its last six months. More about our work: synthema.eu

Today is Europe Day 🇪🇺 #SYNTHEMA brings together partners across Europe to advance AI-powered anonymisation and synthetic data generation for research on rare haematological diseases. 👉https://synthema.eu/ #EuropeDay #HealthInnovation

The #SYNTHEMA and @erneurobloodnet.bsky.social training programme starts this week. The first session is taking place this Friday, 8 May at 12:30 CEST, focusing on infrastructure for synthetic data generation. If you have not registered yet, now is the time. 👉 synthema.eu/training/

Ever heard of synthetic data? It helps protect privacy, improve healthcare innovation, and still relies on real patient data. Your voice matters. Take part in the European survey on synthetic data in healthcare (12–15 minutes), find out more: bit.ly/4c7if0o #SYNTHIA

SYNTHEMA is part of the #HealthData4EU cluster, working to make health data more accessible, secure and interoperable. Its work focuses on synthetic data, federated learning and privacy-preserving technologies. Interested in synthetic data? 👉 Join the webinar series: synthema.eu/training/

Artificial intelligence is already being applied in rare haematological diseases. The #SYNTHEMA and @erneurobloodnet.bsky.social training programme, led by experts from the field, covers synthetic data, federated learning, regulation and clinical use cases. Register: synthema.eu/training/

Sickle Cell Disease is a rare, life-threatening blood disorder with limited treatment options. In SYNTHEMA’s Use Case 2, AI generates synthetic data from 1,000+ patients to study genetic factors & predict brain vascular events, while protecting privacy. 👉 synthema.eu/use-cases/

How will synthetic data be applied in real research? This final session will present use cases in Sickle Cell Disease and Acute Myeloid Leukaemia as part of the joint #SYNTHEMA and @erneurobloodnet.bsky.social training programme. 👉 Register: synthema.eu/training/

#AML is the most common acute leukemia in adults – fast-progressing but treatable. In SYNTHEMA’s Use Case 1, AI creates synthetic data from 2,500+ AML patients to predict survival & treatment responses, while protecting privacy. 👉Learn more about our approach: synthema.eu

How can synthetic health data be standardised, shared and reused across systems? Don’t miss this session on interoperability and synthetic data as part of the joint #SYNTHEMA and @erneurobloodnet.bsky.social training programme. 👉 Register: synthema.eu/training/

#SYNTHEMA enables research on diseases like leukaemia and sickle cell without exposing patient data, using AI-generated synthetic datasets. Our models create realistic clinical, genetic, and imaging data, supporting safe and privacy-first research. 👉 synthema.eu #AIInMedicine

If you're interested in regulation and ethics in AI for healthcare, don’t miss this session on MDR, the EU AI Act and privacy-preserving federated learning as part of the joint #SYNTHEMA and @erneurobloodnet.bsky.social training programme. 👉 Register: synthema.eu/training/

Missed it? The BDVA Healthcare Task Force white paper on synthetic data features #SYNTHEMA, led by Netcompany, alongside AISym4MED and SECURED. It shows how synthetic data can expand access, improve AI and enable more inclusive research. Access the paper: synthema.eu/publications/

Join the first #SYNTHEMA webinar in our training series! 8 May 2026 | 12:30 CEST Explore the @erneurobloodnet.bsky.social infrastructure for synthetic data: governance, strategy & architecture. Open to patients & health professionals. 👉 synthema.eu/training/ Don’t miss it & share!

🚀​Are you ready to explore the cutting-edge world of Artificial Intelligence in hematology? ERN-EuroBloodNet and @synthemaeu.bsky.social are proud to launch a joint educational program on #AI, designed for both the public-at-large and expert audiences. eurobloodnet.eu/education-2/...

Registration is open for the SYNTHEMA & @erneurobloodnet.bsky.social in haematology webinar series. Join all 4 sessions in May 2026 or register for individual webinars. Synthetic data, federated learning, regulation and clinical use cases in AML and SCD. Register: synthema.eu/training/

Good data is not just collected, it is built with care. In #SYNTHEMA, clinical teams across Europe are creating high-quality, privacy-compliant datasets to power synthetic data and AI research in rare blood disorders. 👉Read more: synthema.eu/2025/09/23/d...

Netcompany has published the SYNTHEMA SMPC federated learning app on the Flower Hub. It enables secure aggregation of model updates while keeping data private. 👉 Explore the app: flower.ai/apps/synthem...

Research on rare hematological diseases depends on people committed to complex challenges. Within SYNTHEMA, women contribute across clinical research, data science, technology and project work. Today, on March 8, we spotlight their contributions and give them the recognition they deserve.

At #SYNTHEMA we use AI to fill data gaps & improve care for rare blood disorders. Focusing on Sickle Cell Disease & Acute Myeloid Leukaemia, we integrate clinical, genetic & imaging data for improved patient outcomes. 👉 synthema.eu #RareDiseases #Haematology

28/02 is Rare Disease Day. It is about connection across countries, disciplines and communities. Progress in rare diseases depends on visibility, collaboration and responsible data use. At SYNTHEMA, we support cross-border research in rare hematological diseases synthema.eu

Interested in synthetic data and AI-powered breakthroughs in hematology? Visit SYNTHEMA’s publications section to explore the latest advancements by our team in data privacy, federated learning, AI for rare blood diseases, and more. 👉 Start reading: synthema.eu/publications/ #SYNTHEMA

SYNTHEMA uses smart AI to help scientists study diseases like leukaemia and sickle cell without using real patient data. These models learn from medical records and create new, realistic examples, such as lab results or scans, while keeping privacy fully protected. 👉 synthema.eu

Scientific progress depends on who gets to take part. In #SYNTHEMA, women contribute as researchers, clinicians and data specialists across all stages of the work. This day draws attention to how scientific careers are accessed: synthema.eu/2025/02/11/b...

A worth conference to keep an eye on, with a focus on AI applications and concrete clinical cases in rare diseases, alongside patient perspectives.

At SYNTHEMA, we support cancer research in rare haematological diseases such as Acute Myeloid Leukaemia by developing privacy preserving synthetic clinical and genomic data, helping survival and treatment response research where patient numbers are limited. 👉 Learn more: synthema.eu/use-cases/

It’s not enough for synthetic data to look real, it must be clinically useful. #SYNTHEMA tests if it can predict outcomes, reveal genetic risks & support real diagnoses. Synthetic data means real impact. 👉 synthema.eu #SyntheticData #AIHealthcare

Rare disease research can’t be equitable if data stay scarce or siloed. At SYNTHEMA, we tackle these barriers with GDPR-compliant AI and synthetic data, expanding the evidence base for rare hematological diseases so innovation can benefit patients everywhere. 👉 synthema.eu

Subscribe to the SYNTHEMA newsletter to receive key project updates and announcements about important activities, all in one place. Clear, relevant, and focused on what matters. Choose the format: 📩 by email: f981d420.sibforms.com/serve/MUIEAH... 💼 on LinkedIn: www.linkedin.com/newsletters/...

The Synthema and GenoMed4All consortia have developed an AI framework to refine myeloid neoplasm diagnosis and prognosis. By extracting features from bone marrow images, the team achieved diagnostic accuracy exceeding 90%.

#SYNTHEMA is part of the #HealthData4EU cluster, an alliance of EU-funded projects addressing fragmentation in health data across Europe through synthetic data generation, federated learning, and privacy-preserving technologies. Laarn more: synthema.eu/healthdata4eu/

How can AI improve precision medicine in hematology? The GEMINI Digital Twin platform, developed by the #SYNTHEMA & #GenoMed4Al consortia, integrates multimodal real-world data from 22,080 MDS patients to personalize clinical decision-making. #MDS #Hematology #DigitalTwin

We start this year sharing that registrations are now open for ECRD 2026, taking place on 3–4 June 2026 in Prague and online. The conference addresses European policy priorities on rare diseases, including rare hematological diseases. Early-bird registration is available until 26 February 2026.

A short holiday break is approaching. Wishing partners, colleagues and everyone following #SYNTHEMA a peaceful holiday period, whatever it may look like for you. Thank you for being part of a community committed to responsible research in rare hematological diseases. synthema.eu

PW FedAvg, a new method by UPM researchers, improves treatment effect estimation in federated healthcare settings with imbalanced treatment distributions. It reduces causal inference errors where traditional FL methods fall short. 👉 synthema.eu/publications/ #SYNTHEMA #FederatedLearning

#SYNTHEMA joined the i~HD Annual Conference, with Elisabetta Mezzalira (University of Padova) representing the project. The event featured the presentation of the #HealthData4EU white paper “Building Trust in Synthetic Health Data”. #SyntheticHealthData

How similar is synthetic tabular data to the real thing? This new approach uses KL and JS divergences to evaluate full joint distributions — not just feature by feature. A more reliable way to validate synthetic datasets in practice. 👉 synthema.eu/publications/ #SyntheticData #DataValidation #AI

Over 450 haematological diseases affect blood cells, the lymphatic system & coagulation, posing major challenges to public #HealthSystems. #SYNTHEMA is developing a secure platform for synthetic #ClinicalData to enable GDPR-compliant research in rare #HaematologicalDiseases. 👉 synthema.eu

Can synthetic tabular data be more accurate? This new model by researchers at Universidad Politécnica de Madrid combines a Variational Autoencoder with a Gaussian Mixture Model. Results outperform #CTGAN and #TVAE, especially on medical datasets. 👉 synthema.eu/publications/ #SYNTHEMA

The paper “Distributing trust: A P2P SMPC protocol for secure federated learning” by Petros Demetrakopoulos, Themistoklis Anagnostopoulos and Sofia Tsekeridou (Netcompany RID, #SYNTHEMA partner) will be presented at #FLLM2025 on 27 Nov at 15:30. synthema.eu

#HealthData4EU Cluster is at #EBDVF25 this week. SYNTHEMA isn’t on site, but we’re glad to support tomorrow’s session in Copenhagen. If you're there on 14 Nov, join “Ecosystems of Innovation in Healthcare” from 09:00–10:30, Room 2.B — a chance to hear how our partners advance ethical health data use

How well does synthetic data generation work when spread across multiple hospitals? This study on #AML shows that federated learning protects privacy, though fidelity takes a hit. A key step in real-world AI for rare diseases. 👉 synthema.eu/publications @vicomtech.bsky.social #SYNTHEMA